STOCK TITAN

Windward Bio closes $201M IPO, $50M Sanofi placement

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Windward Bio Group AG (WWB) closed its initial public offering on November 16, 2026, comprising 11,838,234 common shares at $17.00 per share for an aggregate offering amount of $201.2 million. The total included the underwriters’ full option to purchase 1,544,117 additional common shares.

On the same day, the company closed a private placement to Sanofi Foreign Participations B.V. of 1,532,691 common shares and pre-funded warrants to purchase 1,408,485 common shares, in each case at $17.00 per share, for an aggregate purchase price of $50.0 million. The company’s amended and restated articles of association became effective November 14, 2026, in connection with the IPO.

IPO common shares 11,838,234 shares Shares included in the initial public offering closed November 16, 2026
IPO price per share $17.00 per share Public offering price
IPO aggregate offering amount $201.2 million Initial public offering closed November 16, 2026
Underwriters’ option shares 1,544,117 common shares Additional shares included through full exercise of the underwriters’ option
Private placement common shares 1,532,691 shares Concurrent private placement to Sanofi Foreign Participations B.V.
Pre-funded warrant underlying shares 1,408,485 common shares Shares purchasable under pre-funded warrants issued in the concurrent private placement
Private placement aggregate purchase price $50.0 million Concurrent private placement to Sanofi Foreign Participations B.V.
pre-funded warrants financial
"pre-funded warrants to purchase 1,408,485 common shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
underwriters’ option financial
"full exercise of the underwriters’ option"
An underwriters’ option is a provision in a securities offering that lets the group selling the new shares buy a fixed extra amount (often up to 15%) from the issuer after the sale. It acts like a short-term safety valve: if demand is strong, underwriters exercise the option and supply extra shares; if the price falls, they can use the option to stabilize the market. For investors this matters because it affects how many shares come to market, potential short-term dilution, and post-offering price stability—similar to having a reserve supply to smooth out sudden swings.
amended and restated articles of association regulatory
"amended and restated articles of association became effective"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many WWB shares were included in the IPO, and at what price?

The IPO comprised 11,838,234 common shares at $17.00 per share. This included the underwriters’ full exercise of their option to purchase 1,544,117 additional common shares.

What did WWB’s private placement to Sanofi include?

The private placement to Sanofi Foreign Participations B.V. included 1,532,691 common shares and pre-funded warrants to purchase 1,408,485 common shares, each priced at $17.00 per share, for an aggregate purchase price of $50.0 million.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-43537

 

 

Windward Bio Group AG

 

 

Aeschenplatz 6

4052 Basel

Switzerland

(Address of Principal Executive Offices, including zip code)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

 

 
 


INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On November 16, 2026, Windward Bio Group AG (the “Company”) closed its initial public offering (“IPO”) of 11,838,234 common shares, including the full exercise of the underwriters’ option to purchase additional 1,544,117 common shares, at a public offering price of $17.00 per share, for an aggregate offering amount of $201.2 million. On the same day, the Company also closed a concurrent sale of 1,532,691 common shares and pre-funded warrants to purchase 1,408,485 common shares, in each case at $17.00 per share, in a private placement to Sanofi Foreign Participations B.V. for an aggregate purchase price of $50.0 million.

In connection with the IPO, the Company’s amended and restated articles of association became effective on November 14, 2026, a copy of which is attached as Exhibit 3.1, and is incorporated by reference herein.


EXHIBIT INDEX

 

Exhibit No   

Description

3.1    Amended and Restated Articles of Association


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Windward Bio Group AG
By:  

/s/ Scott Applebaum

  Scott Applebaum
  Chief Legal and Corporate Development Officer

Date: November 16, 2026

Filing Exhibits & Attachments

1 document

Other Documents

Keep reading